In hyperkalaemia in a dialysis patient, contact renal team urgently for advice
In patients with DKA, follow Diabetic ketoacidosis guideline

RECOGNITION AND ASSESSMENT

  • ABCDE approach and NEWS system
  • Comprehensive medical and drug history and clinical examination to determine the cause of hyperkalaemia

Symptoms and signs

  • Frequently none, or non-specific neuromuscular symptoms
  • Muscular weakness may occur if blood K+ >7.0 mmol/L
  • Cardiac arrest without warning
  • ECG changes (see Treatment)

Investigations

  • In emergency, measure K+ on a point-of-care blood gas analyser and initiate treatment whilst awaiting the results from a laboratory plasma sample (green top; lithium heparin)
  • HCO3- in venous blood (or from blood gases, if indicated for other reasons) and lactate
  • If serum K+ ≥6.0, urgent 12-lead ECG. If ECG abnormal, or rapid rise in K+ levels and in patients with plasma K+ ≥6.5 mmol/L, continuous 3 lead cardiac monitoring; ideally in a high-dependency setting

Common Causes

  • Artefact: release from blood cells (e.g. during clotting, blood dyscrasias, haemolysis, delayed centrifugation of sample for >2 hr)
  • Low molecular weight heparin
  • Failure of excretion: renal failure, mineralocorticoid deficiency, drugs e.g. spironolactone, amiloride (potassium sparing diuretics), ACE inhibitors (~prils), angiotensin II blockers (~sartans), aliskiren, NSAIDs, ciclosporin, tacrolimus
  • Release from cell: severe tissue damage, acidosis (consider DKA, lactic acidosis)
  • Excess ingestion or supplementation

MANAGEMENT

  • If refractory shock/other organ failure or cause not known, seek advice from ITU and or renal team
  • Protect the heart and lower K+. For guidance follow algorithm (Management of Hyperkalaemia)
  • Treat the underlying cause
Management of Hyperkalaemia
test-flowchart-1

Prevention

  • Consider cause of hyperkalaemia, prevent further rise and recurrence
  • Stop all nephrotoxic medication including ace-inhibitors, angiotensin II receptor blockers, potassium sparing diuretics, NSAIDs and assess diet whilst an inpatient
  • Discuss long-term management plan with parent team before discharge

Monitor

  • Serum K+: at 1, 2, 4, 6 and 24 hr after identification of hyperkalaemia. If K+ >6.5 mmol/L despite medical therapy, seek advice from renal or ITU team
  • Blood glucose: monitor at 0, 15, 30, 60, 90, 120, 180, 240, 300, 360 minutes for a minimum of 6 hr after administration of insulin-glucose infusion

© 2022 The Bedside Clinical Guidelines Partnership.

Created by University Hospital North Midlands and Keele University School of Computing and Mathematics.

Research and development team: James Mitchell, Ed de Quincey, Charles Pantin, Naveed Mustfa